Cytokinetics, Incorporated (CYTK) financial statements (2021 and earlier)

Company profile

Business Address 280 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CA 94080
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:50126819928516411283
Cash and cash equivalents833642125676520
Short-term investments381190156144894663
Other undisclosed cash, cash equivalents, and short-term investments3742(0)1780(0)
Receivables45210047
Contract with customer, asset  5
Other current assets      1
Other undisclosed current assets(31)(39)2(12)(5)10
Total current assets:474234208274159113131
Noncurrent Assets
Property, plant and equipment13534422
Long-term investments and receivables   1780 
Long-term investments   1780 
Other noncurrent assets  00000
Other undisclosed noncurrent assets4652     
Total noncurrent assets:60564211222
TOTAL ASSETS:534290211295170115133
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities27202023221110
Accounts payable8845421
Accrued liabilities191216171885
Employee-related liabilities      4
Debt 53 3  
Deferred revenue and credits1082117
Other liabilities1100   
Other undisclosed current liabilities3   0 (4)
Total current liabilities:31262232333224
Noncurrent Liabilities
Long-term debt and lease obligation464740322715 
Long-term debt, excluding current maturities464540322715 
Operating lease, liability 2
Liabilities, other than long-term debt87 11615017
Deferred revenue and credits1515017
Deferred revenue87 
Other liabilities  11   
Other undisclosed noncurrent liabilities256227122105   
Total noncurrent liabilities:389275163153431517
Total liabilities:420301185185764741
Stockholders' equity
Stockholders' equity attributable to parent113(11)26110946992
Common stock0000000
Additional paid in capital1,105853769756612603589
Accumulated other comprehensive income (loss)011000(0)
Accumulated deficit(992)(865)(743)(646)(518)(535)(497)
Total stockholders' equity:113(11)26110946992
TOTAL LIABILITIES AND EQUITY:534290211295170115133

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenue, net91010
Gross profit:562732131062947
Operating expenses(150)(126)(120)(127)(88)(66)(62)
Operating income (loss):(94)(99)(89)(113)19(37)(15)
Nonoperating income (expense)55430(0)0
Investment income, nonoperating55  000
Interest and debt expense(16)(7)(4)(3)(3)(0) 
Income (loss) from continuing operations before equity method investments, income taxes:(105)(101)(89)(114)16(38)(15)
Other undisclosed income (loss) from continuing operations before income taxes  (18)(14) 0 
Income (loss) before gain (loss) on sale of properties:(105)(101)(106)(128)16(38)(15)
Other undisclosed net loss(23)(21)     
Net income (loss) available to common stockholders, diluted:(127)(122)(106)(128)16(38)(15)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net income (loss):(127)(122)(106)(128)16(38)(15)
Other comprehensive income (loss)(1)000(0)0(0)
Comprehensive income (loss), net of tax, attributable to parent:(128)(122)(106)(128)16(37)(15)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: